A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

BACKGROUND/AIM: Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment. However, treatment with INH is complicated by polymorphisms in the expression of the enzyme system primarily responsible for its elimination, N-acetyltransferase 2 (NAT2), and its associated hep...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Des Devel Ther
Autors principals: Jung, Jin Ah, Kim, Tae-Eun, Lee, Hyun, Jeong, Byeong-Ho, Park, Hye Yun, Jeon, Kyeongman, Kwon, O Jung, Ko, Jae-Wook, Choi, Rihwa, Woo, Hye-In, Koh, Won-Jung, Lee, Soo-Youn
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4598210/
https://ncbi.nlm.nih.gov/pubmed/26491254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S87131
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars